Cormedix Inc. (CRMD): Antony Pfaffle , Interim Chief Medical Officer of Cormedix Inc. sold 10,000 shares on Jun 9, 2016. The Insider selling transaction was reported by the company on Jun 13, 2016 to the Securities and Exchange Commission. The shares were sold at $2.38 per share for a total value of $23,789.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 6, 2016, Matthew Duffy (director) sold 46,106 shares at $2.73 per share price.On Jun 1, 2016, Steven W Lefkowitz (director) sold 50,000 shares at $2.95 per share price.Also, On May 26, 2016, Cora M Tellez (director) purchased 8,600 shares at $2.90 per share price.On May 25, 2016, Antony Pfaffle (Interim Chief Medical Officer) sold 12,700 shares at $2.74 per share price.
Shares of CorMedix (CRMD) ended Friday, Jun 10, 2016 session in red amid volatile trading. The shares closed down -0.1 points or -4.31% at $2.22 with 3,96,084 shares getting traded. Post opening the session at $2.27, the shares hit an intraday low of $2.15 and an intraday high of $2.52 and the price vacillated in this range throughout the day. The company has a market cap of $80 M and the number of outstanding shares has been calculated to be 3,62,18,323 shares. The 52-week high of CorMedix is $5.7999 and the 52-week low is $1.15.
Company has been under the radar of several Street Analysts.CorMedix is Reiterated by FBR Capital to Outperform while Lowering the Price Target of the company shares to $ 6 from a previous price target of $7 . The Rating was issued on Mar 17, 2016.
CorMedix Inc. (CorMedix) is a pharmaceutical company that in-licenses develops and commercializes prophylactic and therapeutic products for the treatment of infectious diseases in cardiac renal and oncology patients. The Company has in-licensed all of the products in its pipeline. The Company’s primary product is Neutrolin a catheter lock solution which is used the treatment of catheter-related infections and thrombosis in the central venous catheter markets such as dialysis critical care and oncology. It has the worldwide rights to develop and commercialize product candidates CRMD003 (Neutrolin) and CRMD004. The Company manufactures CRMD003 (Neutrolin) through Navinta LLC a United States-based active pharmaceutical ingredient (API) developer. The CRMD004 is the gel formulation of Neutrolin which is in the pre-clinical stage of development.